{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1"},{"groupId":"OG001","value":"18.9"},{"groupId":"OG002","value":"29.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"},{"groupId":"OG002","value":"89"}],"units":"Participants"}],"description":"Cytogenetic response was defined as the percentage of Ph+ metaphases in bone marrow (peripheral blood may not be used), with a review of a minimum of 20 metaphases. CCyR was defined as 0% Ph+ metaphases.","groups":[{"description":"Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG000","title":"Treatment Period: Cohort A: Ponatinib 45 mg"},{"description":"Participants received ponatinib 30 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG001","title":"Treatment Period: Cohort B: Ponatinib 30 mg"},{"description":"Participants received ponatinib 15 mg orally once daily in each 28-day cycle.","id":"OG002","title":"Treatment Period: Cohort C: Ponatinib 15 mg"}],"paramType":"NUMBER","populationDescription":"ITT Cytogenetic Population included all participants who were randomized and had a cytogenetic assessment at Baseline with ≥20 metaphases examined, regardless of whether they received the assigned study drug. Overall number of participants analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","timeFrame":"Month 12","title":"Percentage of Participants With Complete Cytogenetic Response (CCyR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}